中国Court CasesCourtsInfringementPatent LawSupreme People's CourtTrademark
2024年1月9日

Twice the Trouble: Unraveling a Single Case of Dual Patent and Trademark Infringement

by
王怡瑾女士
车李晓芸女士

Can a rights holder sue the same infringer separately based on one single infringing act that infringes both trademark and patent rights? An interesting case this year from China’s Supreme People’s Court that addresses this specific issue ((2023)最高法知民终235号).

Beijing Run De Hong Tu Technology Development Co., Ltd. (“Run De Hong Tu”) sued an individual named Li XX1 for patent infringement based on his activities as a small retailer selling a certain sewage pipe branded as “Submarine”. In fact, Run De Hong Tu had initiated multiple similar lawsuits, primarily targeting small and micro retailers, and had been able to secure substantial compensation in these cases.

Run De Hong Tu, along with its affiliated company, Bo Rui Run Xing Co., Ltd., employed a strategic approach in their litigation activities. First, Bo Rui Run Xing reached a one-time settlement agreement with small and micro retailer Li XX over a trademark right dispute. This settlement, however, did not address any patent right issues. Li XX did not conduct any further infringement thereafter. However, Run De Hong Tu subsequently initiated a separate lawsuit against Li XX for the same sales activities, but this time alleging patent infringement.

The Supreme People’s Court (second-instance court), in its judgment emphasized that Run De Hong Tu's conduct violated the principle of honesty and credibility and constituted an abuse of rights. The court highlighted that both Run De Hong Tu and Bo Rui Run Xing were aware that the sales activities in question infringed both trademark and patent rights, in view of their experience in IP litigations. Bo Rui Run Xing's omission of the patent right issue in the settlement and Run De Hong Tu's subsequent lawsuit appeared to be a calculated move to obtain additional compensation.

Furthermore, the court criticized the companies for targeting small and micro retailers instead of focusing on the source of the infringement. This approach not only increased the legal and financial burdens on the defendants but also led to an unreasonable use of judicial resources. As a result, the court dismissed Run De Hong Tu's appeal, upheld the original judgment, and ordered Run De Hong Tu to compensate Li XX for reasonable expenses incurred in the lawsuit amounting to 1,000 yuan.

EIP Thoughts

  1. There’s nothing in the Chinese patent law that says one should sue the manufacturer versus the retailer, although China’s litigation system has always leaned in that direction (e.g., methods of medical treatment are not patent eligible, but claims directed to the manufacture of a medicament are patentable). This case is interesting in that the SPC clearly indicated that suing small and micro retailers is not the optimal way to uphold patent rights. Small and micro retailers may not have an obvious intent to infringe, and do not have the resources to defend themselves. Interestingly, the court decided against the patentee not because there was no patent infringement, but because of the litigation strategy. Foreign companies should definitely pay attention to this nuance of Chinese litigation.
  2. In the new Chinese Patent Law, New Article 20 codified guiding principles into the patent law that included statements about patent applications “following principles of good faith” and “not harming public interest or the legitimate rights or interests of others”. In this case, the court concluded that the IP rights holder was involved in “misleading settlements” and ”suing twice for the same matter.” In other similar lawsuits, the court brought up "induced infringement" and “trap evidence gathering,” as other forms of abusive behaviours which violated principle of honesty and credibility. It’s clear that such types of more aggressive litigation strategies should be avoided, or at least used cautiously in China.
  3. Beyond just strengthening the judicial protection of intellectual property rights, China appears to also be attempting to regulate how IP rights holders exercise their rights, with the ultimate goal of reducing unnecessary litigation cases and avoiding the misuse of judicial resources.

If you would like to have more information on this matter or would like to have our advice, please feel free to contact us at [email protected].

This article is for general informational purposes only and should not be considered legal advice or a legal opinion on a specific set of facts.

  1. full name redacted by the Court ↩︎

其他文章

Hong Kong Launches New Original Grant Patent System

2019年12月17日
Hong Kong will be launching a new patent system on December 19, 2019 that includes key changes, most notably the introduction of an original grant patent system. This new patent system includes both the Patents (Amendment) Ordinance 2016 and the Patents (General) (Amendment) Rules 2019. Currently, there are two types of patent applications available in […]

Beijing Supreme People’s Court Upholds Novo Nordisk Semaglutide Patent in China based on Post-Filing Data

2026年1月23日
On December 31, 2025, The Supreme People's Court upheld the Beijing IP Court's decision, meaning that the semaglutide patent remains valid and will expire on March 20, 2026. Novo Nordisk announced this positive news via a press release on the day the case was decided. The Chinese Ministry of Commerce has also confirmed this decision […]

Is “Comparable” the New “Unexpected”? China’s SPC Relaxes Inventive Step Standard for Breakthrough Therapeutics

2026年7月14日
How the Supreme People's Court Established a New Benchmark for Unexpected Technical Effects in a Landmark Diabetic Nephropathy Case Proving inventive step for pharmaceutical compounds, especially a second medical use, remains one of the most challenging aspects of patent prosecution in China. When the prior art discloses a compound's general therapeutic properties, how can an […]

What Microsoft’s Recent Patent Invalidation Case in China Teaches Us About User Interface Patents

2026年1月29日
Each year the CNIPA publishes its Top Ten Patent Re-examination and Invalidation Cases for the previous year. These cases are meant to be guiding cases, showcasing exemplary real-world decisions that clarify certain aspects of the law. Today we’ll be sharing about one of the Top 10 Invalidation Cases in 2024 involving Microsoft (China) Co., Ltd. […]

我们的过去活动

Top crossarrow-right